Genetics and variable drug response

JAMA

Volumn 306, Issue 3, 2011, Pages 306-307

  Wilke, Russell A ^a   Dolan, M Eileen ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBAMAZEPINE; CLOPIDOGREL; CYTOCHROME P450; FLUCLOXACILLIN; HLA A ANTIGEN; HLA B ANTIGEN; MERCAPTOPURINE; SIMVASTATIN; THIOPURINE METHYLTRANSFERASE; WARFARIN;

BONE MARROW SUPPRESSION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH CARE COST; HUMAN; LIVER INJURY; MEDICAL INFORMATION; NOTE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 79960537881     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.998     Document Type: Note

References (10)

1. Relling MV, Gardner EE, Sandborn WJ, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387-391.
2. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
3. Klein TE, Altman RB, Eriksson N, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data [published correction appears in N Engl J Med. 2009;361(16):1613]. N Engl J Med. 2009;360(8):753-764.
4. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010;55(25):2804-2812.
5. Chen P, Lin JJ, Lu CS, et al; Taiwan SJS Consortium. Carbamazepine- induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126-1133.
6. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-1143.
7. Daly AK, Donaldson PT, Bhatnagar P, et al; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816-819.
8. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
9. Link E, Parish S, Armitage J, et al; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008;359(8):789-799.
10. Table of pharmacogenomic biomarkers in drug labels. US Food and Drug Administration. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm. Accessed June 23, 2011.